Central nervous system biomarkers are measurable indicators used to determine or evaluate pathogenic processes and therapeutic interventions and predict treatment response. Biomarker captures what is happening in a cell or an organism at a given moment, and can serve as early warning systems for health. Thus, they are used in various scientific fields. Central nervous system biomarkers can be used in drug development as they have the potential to improve the development process and efficiency of drug discovery.
Moreover,
these biomarkers provide information about the patient at almost every stage of
care. It is a rapidly growing field that is taking advantage of unprecedented
scientific, technological, and computational advances, as well as cover
research on biochemical, functional, or physical indicators of a wide variety
of diseases. Central nervous system biomarkers may help detect or confirm the
presence of a disease, or identify a person with a subtype of disease.
Biomarkers are measurable but do not define how an individual feels or
functions.
The
Central
nervous system biomarkers market report also includes a comprehensive
business analysis of the current state of the industry, which examines
innovative business.
Biomarkers
help to understand the development of diseases, their relationship to
environmental chemicals, and identify subjects at high risk of developing the disease.
Moreover, biomarkers play an important role in understanding disease mechanimechanismsprove
the quality of patient care. Biomarkers can be used to identify several chronic
and neurodegenerative diseases at an early stage, provide enhanced diagnosis,
and eventually better treatment. In short, biomarkers can be used to
diagnose/predict disease, monitor disease progression, and predict treatment
response.
Therefore,
with the increasing prevalence of chronic and neurodegenerative diseases, the use
of central nervous system biomarkers is also increasing. For example, according
to the Centers for Disease Control and Prevention (CDC), in 2020, as many as
5.8 million people in the United States were living with Alzheimer's, and the
number doubles every 5 years. This number is expected to reach around 14
million individuals by 2060.